Light-Responsive LNPs: VEGFA Editing for CNV Suppression

bioRxiv

Overview

Researchers developed a light-responsive lipid nanoparticle (LNP) platform to deliver Cas9 RNP for the spatially controlled editing of the VEGFA gene. In a rat model of choroidal neovascularisation (CNV), a single intravitreal injection combined with light illumination significantly reduced vascular leakage and structural abnormalities. This approach addresses the safety risks associated with unrestricted VEGFA loss while reducing the treatment burden of repeated injections.

In Depth

Key Findings

The study demonstrates that light-responsive lipid nanoparticles can deliver Cas9/sgRNA ribonucleoprotein (RNP) complexes to enable controlled genome editing of VEGFA. In human retinal pigment epithelial cells, light exposure increased the extent of VEGFA disruption compared to non-illuminated conditions, resulting in a corresponding decrease in VEGFA mRNA and protein expression. In a laser-induced rat CNV model, the combination of a single intravitreal injection and light illumination significantly reduced CNV-associated structural abnormalities and vascular leakage compared to vehicle and non-illuminated controls.

Technical Details

The developed LNP platform exhibits the following specifications:

• Mean hydrodynamic diameter: approximately 130 nm.
• Polydispersity: 0.296.
• sgRNA encapsulation efficiency: 90.33%.

The platform utilizes light illumination as the trigger for the release of the Cas9 RNP complexes. Targeted next-generation sequencing was used to confirm the extent of VEGFA disruption in human cells. Ocular safety assessments indicated no apparent nanoparticle-related structural abnormalities in the retina.

Background and Context

Choroidal neovascularisation (CNV) is a primary cause of irreversible vision loss. Current anti-VEGF therapies typically require repeated intravitreal injections, which increase the cumulative risk and treatment burden for patients. While genome editing offers a potential one-time durable suppression of VEGFA, unrestricted loss of the protein can lead to choriocapillaris atrophy and compromised retinal function, creating a significant safety barrier for clinical translation.

Significance and Outlook

By introducing light-controlled release, this platform allows for spatially controlled genome editing, mitigating the risks of total VEGFA depletion. This research provides a foundation for treating VEGFA-driven macular neovascular disease through a method that balances long-term efficacy with precise safety controls.

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

• Your email and selected fields are used only to deliver the newsletter.
• We never share your information with third parties.
• You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Agree & Continue ▶

Takes about a minute · Unsubscribe anytime